BIIB Biogen Inc.

233.6
-0.02  -0%
Previous Close 233.62
Open 234.3
Price To Book 3.27
Market Cap 45,293,497,539
Shares 193,893,397
Volume 103,598
Short Ratio
Av. Daily Volume 1,742,752

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 6-Month data due 2Q 2019 with initial Phase 2/3 data due mid-2019.
NSR-RPGR
X-linked Retinitis Pigmentosa
Phase 3 STAR trial initiation announced March 5, 2018. Enrollment to be completed 1H 2019 with data due 2020.
NSR-REP1
Choroideremia
Phase 2 data due 2H 2020.
BIIB054
Parkinson's disease
Phase 2 data due 1H 2020.
Natalizumab - OPUS
Epilepsy
Phase 3 commencement of enrollment announced September 4, 2018.
BIIB093
Large hemispheric infarction
Phase 3 ready to be initiated. Acquired from Remedy Pharmaceuticals May 15, 2017.
CIRARA (intravenous glyburide)
Ischemic stroke
Phase 2 data due 2H 2019.
BIIB092 - Anti Tau
Progressive supranuclear palsy (PSP)
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD2)
Alzheimer’s disease
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - EMERGE
Alzheimer’s disease
Phase 3 trial to be initiated later in 2019.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD1)
Alzheimer’s disease
Phase 2b data due mid-2020.
Opicinumab (AFFINITY)
Multiple sclerosis (MS)
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - ENGAGE
Alzheimer’s disease
Phase 2b data released February 8, 2018 - primary endpoint not met.
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2 data released September 2018 - primary endpoint not met.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 topline data showed no statistically significant treatment effect for primary and secondary endpoints - 1Q 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Erythromelagia
Phase 2 data due by end of 2019.
BIIB059 (anti-BDCA2)
Lupus
Phase 2b data released October 23, 2018 - primary endpoint not met.
Dapirolizumab pegol (anti-CD40L)
Lupus
Phase 3 initiation announced March 22. 2019.
BAN2401
Alzheimer’s disease
Phase 2b trial initiated September 2018.
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
Phase 1/2 data released June 8, 2017.
XLRS Gene Therapy
X-linked retinoschisis (XLRS)
NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 data due 2H 2020.
IONIS-SOD1Rx / BIIB067
Amyotrophic lateral sclerosis (ALS)
Phase 3b trial initiation announced January 3, 2019.
Natalizumab - NOVA
Multiple sclerosis (MS)
Phase 2b data due late-2020.
BIIB104
Cognitive Impairment Associated With Schizophrenia (CIAS)
Phase 2 data due late-2020.
TMS-007
Stroke
Phase 2 data due late-2020.
BIIB074 (Nav1.7 inhibitor)
Small Fibre Neuropathy

Latest News

  1. Amgen & Novartis' Alzheimer Studies End in Another Failure
  2. 2 Falling Pharma Stocks Whose Star May Rise in 2019
  3. Will Patent Woes Boost Pharma Stock Megamergers Further?
  4. Federal judge blocks Trump Administration's proposal to include wholesale drug prices in TV ads
  5. Top Analyst Reports for Boeing, 3M & U.S. Bancorp
  6. Skyhawk Therapeutics adds Merck to nest of drug partners
  7. Why Biogen Stock Has Plummeted in 2019
  8. Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
  9. Biogen Revenue Has the Potential to Meet Wall Street Expectations, Analyst Says
  10. Is Biogen Inc.'s (NASDAQ:BIIB) ROE Of 34% Impressive?
  11. Here are the Mass. firms with the highest — and lowest — profits per employee
  12. Why These 4 Biotech Leaders Could Rebound On Strong Earnings
  13. 2 Health Care Companies to Consider for the 2nd Half of the Year
  14. Atara Reports Initial Data for Multiple Sclerosis Candidate
  15. Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
  16. 3 Top Biotech Stocks to Buy Right Now
  17. Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy
  18. Options Bulls Continue to Blitz Embattled Biogen Stock
  19. Biogen Drops After Piper Jaffray Downgrade, Price Target Cut